


PHARMACEUTICAL 2019

Monopar Therapeutics

Monopar Therapeutics Rank 180 of 371



RealRate

PHARMACEUTICAL 2019

Monopar Therapeutics

Monopar Therapeutics Rank 180 of 371

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 377% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is -143%, being 189% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	7,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	400
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-2.4
Other Expenses	-72
Other Liabilities	0
Other Net Income	103
Property and Equipment	0
Research and Development	1,774
Revenues	0
Selling, General and Administrative Expense	1,628

Output Variable	Value in 1000 USD
Assets	7,318
Liabilities	400
Expenses	3,331
Stockholders Equity	6,918
Net Income	-3,228
Comprehensive Net Income	-3,229
Economic Capital Ratio	-143%